Alexion has announced that four members of the company’s C-suite team are set to leave the company, following an internal investigation into sales practices.
Chief financial officer Dave Anderson is among the casualties, who while just joining the company this past December is set to resign in August. Alexion will also lose its R&D chief, Martin Mackay, to retirement. EVP and head of human resources Clare Carmichael and commercial chief Carsten Thiel are leaving as well, with Thiel’s replacement, Brian Goff, already hired.
Alexion has completely remade its executive makeup, which began when former CEO David Hallal lost investor confidence amid sales fraud investigations that demonstrated that the company inappropriately pressured staff to pad sales of its Soliris treatment.
> Read the Wall Street Journal report
Source: Pharmaceutical Manufacturing
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.
